A single‐centre, open‐label, single‐arm, fixed‐sequence pharmacokinetic study of SHR3680 on repaglinide and bupropion in prostate cancer patients

To evaluate the pharmacokinetic effects of SHR3680 on repaglinide and bupropion and its metabolite hydroxybupropion. METHODS: A single‐centre, open‐label, single‐arm, fixed‐sequence clinical trial in 18 patients with prostate cancer. RESULTS: After a single oral dose of 0.5 mg repaglinide and SHR368...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Tao, Xu, Zhenzhou, Huang, Liang, Wang, Yike, Zeng, Gongqian, Ye, Mingji, Liu, Kan, Zeng, Fuhua, Jiang, Shusuan, Han, Weiqing, Cao, Jingying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092624/
https://www.ncbi.nlm.nih.gov/pubmed/36098470
http://dx.doi.org/10.1111/bcp.15528

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092624/
https://www.ncbi.nlm.nih.gov/pubmed/36098470
http://dx.doi.org/10.1111/bcp.15528

Ejemplares similares